Clinical utility of asthma biomarkers: from bench to bedside

Susanne JH Vijverberg,1,2,* Bart Hilvering,2,* Jan AM Raaijmakers,1 Jan-Willem J Lammers,2 Anke-Hilse Maitland-van der Zee,1,* Leo Koenderman2,* 1Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vijverberg SJH, Hilvering B, Raaijmakers JA, Lammers JW, Maitland-van der Zee AH, Koenderman L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/348ae29b0f974485abe0fad6031c8748
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:348ae29b0f974485abe0fad6031c8748
record_format	dspace
spelling	oai:doaj.org-article:348ae29b0f974485abe0fad6031c87482021-12-02T04:59:46ZClinical utility of asthma biomarkers: from bench to bedside1177-54751177-5491https://doaj.org/article/348ae29b0f974485abe0fad6031c87482013-08-01T00:00:00Zhttp://www.dovepress.com/clinical-utility-of-asthma-biomarkers-from-bench-to-bedside-a14198https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Susanne JH Vijverberg,1,2,* Bart Hilvering,2,* Jan AM Raaijmakers,1 Jan-Willem J Lammers,2 Anke-Hilse Maitland-van der Zee,1,* Leo Koenderman2,* 1Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands; 2Department of Respiratory Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands *These authors contributed equally to this work Abstract: Asthma is a chronic disease characterized by airway inflammation, bronchial hyperresponsiveness, and recurrent episodes of reversible airway obstruction. The disease is very heterogeneous in onset, course, and response to treatment, and seems to encompass a broad collection of heterogeneous disease subtypes with different underlying pathophysiological mechanisms. There is a strong need for easily interpreted clinical biomarkers to assess the nature and severity of the disease. Currently available biomarkers for clinical practice – for example markers in bronchial lavage, bronchial biopsies, sputum, or fraction of exhaled nitric oxide (FeNO) – are limited due to invasiveness or lack of specificity. The assessment of markers in peripheral blood might be a good alternative to study airway inflammation more specifically, compared to FeNO, and in a less invasive manner, compared to bronchoalveolar lavage, biopsies, or sputum induction. In addition, promising novel biomarkers are discovered in the field of breath metabolomics (eg, volatile organic compounds) and (pharmaco)genomics. Biomarker research in asthma is increasingly shifting from the assessment of the value of single biomarkers to multidimensional approaches in which the clinical value of a combination of various markers is studied. This could eventually lead to the development of a clinically applicable algorithm composed of various markers and clinical features to phenotype asthma and improve diagnosis and asthma management. Keywords: asthma, airway inflammation, biological markers, pharmacogenomics, metabolomicsVijverberg SJHHilvering BRaaijmakers JALammers JWMaitland-van der Zee AHKoenderman LDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2013, Iss default, Pp 199-210 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Vijverberg SJH Hilvering B Raaijmakers JA Lammers JW Maitland-van der Zee AH Koenderman L Clinical utility of asthma biomarkers: from bench to bedside
description	Susanne JH Vijverberg,1,2,* Bart Hilvering,2,* Jan AM Raaijmakers,1 Jan-Willem J Lammers,2 Anke-Hilse Maitland-van der Zee,1,* Leo Koenderman2,* 1Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands; 2Department of Respiratory Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands *These authors contributed equally to this work Abstract: Asthma is a chronic disease characterized by airway inflammation, bronchial hyperresponsiveness, and recurrent episodes of reversible airway obstruction. The disease is very heterogeneous in onset, course, and response to treatment, and seems to encompass a broad collection of heterogeneous disease subtypes with different underlying pathophysiological mechanisms. There is a strong need for easily interpreted clinical biomarkers to assess the nature and severity of the disease. Currently available biomarkers for clinical practice – for example markers in bronchial lavage, bronchial biopsies, sputum, or fraction of exhaled nitric oxide (FeNO) – are limited due to invasiveness or lack of specificity. The assessment of markers in peripheral blood might be a good alternative to study airway inflammation more specifically, compared to FeNO, and in a less invasive manner, compared to bronchoalveolar lavage, biopsies, or sputum induction. In addition, promising novel biomarkers are discovered in the field of breath metabolomics (eg, volatile organic compounds) and (pharmaco)genomics. Biomarker research in asthma is increasingly shifting from the assessment of the value of single biomarkers to multidimensional approaches in which the clinical value of a combination of various markers is studied. This could eventually lead to the development of a clinically applicable algorithm composed of various markers and clinical features to phenotype asthma and improve diagnosis and asthma management. Keywords: asthma, airway inflammation, biological markers, pharmacogenomics, metabolomics
format	article
author	Vijverberg SJH Hilvering B Raaijmakers JA Lammers JW Maitland-van der Zee AH Koenderman L
author_facet	Vijverberg SJH Hilvering B Raaijmakers JA Lammers JW Maitland-van der Zee AH Koenderman L
author_sort	Vijverberg SJH
title	Clinical utility of asthma biomarkers: from bench to bedside
title_short	Clinical utility of asthma biomarkers: from bench to bedside
title_full	Clinical utility of asthma biomarkers: from bench to bedside
title_fullStr	Clinical utility of asthma biomarkers: from bench to bedside
title_full_unstemmed	Clinical utility of asthma biomarkers: from bench to bedside
title_sort	clinical utility of asthma biomarkers: from bench to bedside
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/348ae29b0f974485abe0fad6031c8748
work_keys_str_mv	AT vijverbergsjh clinicalutilityofasthmabiomarkersfrombenchtobedside AT hilveringb clinicalutilityofasthmabiomarkersfrombenchtobedside AT raaijmakersja clinicalutilityofasthmabiomarkersfrombenchtobedside AT lammersjw clinicalutilityofasthmabiomarkersfrombenchtobedside AT maitlandvanderzeeah clinicalutilityofasthmabiomarkersfrombenchtobedside AT koendermanl clinicalutilityofasthmabiomarkersfrombenchtobedside
_version_	1718400881262592000

Clinical utility of asthma biomarkers: from bench to bedside

Ejemplares similares